Your browser doesn't support javascript.
loading
Follistatin as a Potential Biomarker for Identifying Metabolically Healthy and Unhealthy Obesity: A Cross-Sectional Study.
Erbakan, Ayse N; Mutlu, H Hicran; Uzunlulu, Mehmet; Castur, Lütfullah; Akbas, Muhammet Mikdat; Kaya, Fatos N; Erbakan, Mehmet; Isman, Ferruh K; Oguz, Aytekin.
Afiliación
  • Erbakan AN; Department of Internal Medicine, Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Kadikoy, 34722 Istanbul, Turkey.
  • Mutlu HH; Department of Family Medicine, Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Kadikoy, 34722 Istanbul, Turkey.
  • Uzunlulu M; Department of Internal Medicine, Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Kadikoy, 34722 Istanbul, Turkey.
  • Castur L; Department of Internal Medicine, Istanbul Mehmet Akif Ersoy Thoracic and Cardiovascular Surgery Training and Research Hospital, 34303 Istanbul, Turkey.
  • Akbas MM; Department of Internal Medicine, Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Kadikoy, 34722 Istanbul, Turkey.
  • Kaya FN; Department of Internal Medicine, Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Kadikoy, 34722 Istanbul, Turkey.
  • Erbakan M; Department of Family Medicine, Health Sciences University, Kartal Dr. Lutfi Kirdar City Hospital, Kartal, 34865 Istanbul, Turkey.
  • Isman FK; Department of Biochemistry, Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Kadikoy, 34722 Istanbul, Turkey.
  • Oguz A; Department of Internal Medicine, Istanbul Medeniyet University, Goztepe Prof. Dr. Suleyman Yalcin City Hospital, Kadikoy, 34722 Istanbul, Turkey.
J Pers Med ; 14(5)2024 May 03.
Article en En | MEDLINE | ID: mdl-38793069
ABSTRACT
Metabolically healthy obesity (MHO) refers to obese individuals with a favorable metabolic profile, without severe metabolic abnormalities. This study aimed to investigate the potential of follistatin, a regulator of metabolic balance, as a biomarker to distinguish between metabolically healthy and unhealthy obesity. This cross-sectional study included 30 metabolically healthy and 32 metabolically unhealthy individuals with obesity. Blood samples were collected to measure the follistatin levels using an enzyme-linked immunosorbent assay (ELISA). While follistatin did not significantly differentiate between metabolically healthy (median 41.84 [IQR, 37.68 to 80.09]) and unhealthy (median 42.44 [IQR, 39.54 to 82.55]) individuals with obesity (p = 0.642), other biochemical markers, such as HDL cholesterol, triglycerides, C-peptide, and AST, showed significant differences between the two groups. Insulin was the most significant predictor of follistatin levels, with a coefficient of 0.903, followed by C-peptide, which exerted a negative influence at -0.624. Quantile regression analysis revealed nuanced associations between the follistatin levels and metabolic parameters in different quantiles. Although follistatin may not serve as a biomarker for identifying MHO and metabolically unhealthy obesity, understanding the underlying mechanisms that contribute to metabolic dysfunction could provide personalized strategies for managing obesity and preventing associated complications.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Pers Med Año: 2024 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Pers Med Año: 2024 Tipo del documento: Article País de afiliación: Turquía Pais de publicación: Suiza